EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Vytrus Biotech S.A. (VYT) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Vytrus Biotech S.A. €13.94, price €16.20, upside -14.0%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · ES · ISIN ES0105618005

VB Broad data Sep 23, 2026

Vytrus Biotech S.A.

VYT · MC

Overvalued / MonitorQuality growthQuality is not strong enough to offset the price risk.

!Fair value €13.94 · Overvalued (−14%)
✓Quality 65/100
!Expensive Growth (revenue 5y +37.5 %/yr)
✓Highly profitable · 29.9% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (7/13)
✓Wide moat 90/100
!Weak on valuation: 15 out of 100
Watch Vytrus Biotech S.A. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€19.80 €1.84 Fair Value €13.94 Mar 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

54‑month range €1.84 – €19.80 · fair‑value band €5.72 – €17.52 · the €16.20 price screens above the €13.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Vytrus Biotech in your weekly email

Every Wednesday you see whether Vytrus Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally.

Show more

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects against oxidative stress. The company also provides Baolift that improves muscle tone and facial complexion; Elaya Renova that boosts hair tensegrity; Kannabia Sense, a prebiotic treatment that stimulates the skin microbiota to produce an in-situ postbiotic cocktail; Quora Noni to avoid the attack of skin harmful bacteria; Centella Reversa for facial complexion improvement; and Arabian Cotton to protect and repair cell structures against sun damage. In addition, it offers Photobiome, a prebiotic active that fights the skin photoageing process; Nectaria Lithops, an active ingredient that biophysically optimizes the skin microenvironment and vitamin D levels; Olea Vitae, a cellular oil against ageing; Turmeria Zen for skin hydration and wrinkles on stressed profiles; and Sensia Carota, a plant-based active that protects and prevents from the damage on sensitive and sensitized skins. Further, the company provides technology solutions, such as plasma rich in cell factors; phyto-peptidic, phyto-lipidic, and phyto-glucidic fractions; and phyto-cell fusions, as well as Vytrus TV to create an audiovisual space with added value for cosmetic formulation. It exports its products. Vytrus Biotech, S.A. was incorporated in 2009 and is headquartered in Barcelona, Spain.

Stock analysis

Vytrus Biotech S.A. (VYT) currently trades at €16.20, while our model-based Fair Value estimate is €13.94, implying the stock looks roughly 16.2% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of €17.90 per share, and 2 of the 24 models we run sit above the €16.20 price.

Bear case: the Economic Profit group reads lowest at €2.78, and 22 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: €5.72 (bear) to €17.52 (bull), the price of €16.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Vytrus Biotech S.A. reported revenue of €8.4M in FY2025 versus €2.8M in FY2021, a compound +31.4%/yr. Reported net income was €2.9M in FY2025, compounding +59.3%/yr from FY2021.

Key figures

Market cap €132M · P/E ratio 42.6 · P/S ratio 14.7 · EPS (TTM) €0.3800 · Net margin 34.6% · Return on equity 32.9% · Return on assets (EBIT) 9.9% · Operating margin 32.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 197% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −14%, VYT screens richer than that median.

Fair Value models

Bear €5.72 Fair Value €13.94 Bull €17.52
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.2790 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF €2.17 €2.94 €5.20 76
Growth DCF €2.05 €3.16 €4.89 75
Owner Earnings €2.01 €3.71 €6.68 71
All 24 models by family
DCF Models
FCF DCF €2.17 €2.94 €5.20 76
Owner Earnings €2.01 €3.71 €6.68 71
5Y Revenue Exit €2.55 €4.31 €8.02 67
5Y EBITDA Exit €4.68 €8.62 €16.35 69
5Y P/E Exit €5.04 €11.71 €20.92 65
10Y Revenue Exit €2.32 €4.88 €6.53 64
10Y EBITDA Exit €3.73 €8.79 €17.86 61
10Y P/E Exit €3.95 €9.44 €18.69 57
Earnings-Based
Graham-Dodd €2.62 €18.28 €25.65 61
Lynch FV €9.44 €13.49 €17.53 59
PEG = 1.0 €9.44 €13.49 €17.53 55
EPV €2.63 €2.92 €3.15 71
Multiples
P/E Multiple €6.36 €8.48 €10.60 63
P/S Multiple €2.92 €3.90 €4.87 58
P/B Multiple €4.63 €6.17 €7.71 55
EV/EBIT €5.64 €7.44 €9.24 66
EV/EBITDA €6.05 €7.99 €9.92 67
EV/Revenue €2.58 €3.59 €4.59 54
Asset-Based
NCAV (Graham) €0.6900 €0.9200 €1.37 54
Growth DCF
Growth DCF €2.05 €3.16 €4.89 75
Rev-Margin DCF €2.79 €4.89 €9.28 67
Economic Profit
Residual Income €2.03 €2.78 €13.01 56
ROIC Compounder €3.23 €4.45 €5.61 70
Growth Earnings
Growth-Adj P/E €12.53 €17.90 €23.28 65

Open the full fair value analysis →

Notify me when VYT reaches fair value

Put VYT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 65/100

Of which business quality 64 · Market factors (momentum, volatility) 65

Profitability 86
Margins and returns on capital today
Quality Growth 79
Are margins and returns improving?
Cashflow 55
Earnings quality: real cash, not paper profit
Fin. Strength 76
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 62
Price trend over the last 3–12 months (market factor)
52W Momentum 87
Distance to the 52-week high (market factor)
Net Issuance 66
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+66.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.5%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+56.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+56.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 38%
2025 sits 336% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+54.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +51.1% a year for the price.

VYT screens 16% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Vytrus Biotech S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 65 · Top 25%
Fair Value upside −14% · Above median
Profitability
Return on equity (TTM) 33% · Top 25%
Return on assets 15% · Top 25%
Net margin (TTM) 30% · Top 25%
Operating margin (TTM) 33% · Top 25%
Growth and dividend
Revenue growth 53% · Top 25%
Balance sheet
Debt / equity 0.15× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 42.6× · Pricier than median
P/B 14.52× · Priciest 25%
P/S (TTM) 15.44× · Priciest 25%
P/FCF 122.6× · Priciest 25%
EV/EBITDA 43.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)93 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vytrus Biotech S.A. · Fair Value
€13.94 −16%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Vytrus Biotech S.A. Fair Value". https://www.fairvalue-calculator.com/stock/VYT

Frequently asked questions

Is Vytrus Biotech S.A. (VYT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €13.94 versus a price of €16.20, about −14% upside (overvalued).
What is the fair value of VYT?
Our model-based fair value for Vytrus Biotech S.A. is €13.94 (as of Sep 23, 2026), built from audited fundamentals. The current price: €16.20.
What is the quality score of VYT?
Vytrus Biotech S.A. has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vytrus Biotech S.A. (VYT)?
Our model-based price target is the fair value of €13.94 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario €5.72, optimistic scenario €17.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Vytrus Biotech S.A. stock forecast for 2026?
Our models put fair value at €13.94, about −14% upside versus a price of €16.20 (overvalued). Cautious scenario €5.72, optimistic scenario €17.52. The calculation is refreshed regularly with new filings.
What is the revenue of Vytrus Biotech S.A. (VYT)?
Vytrus Biotech S.A. reported trailing-twelve-month revenue of about €9.7M (latest available figure, as of Sep 23, 2026).
What growth is priced into Vytrus Biotech S.A. (VYT)?
For today's price to be fair in a discounted-cash-flow model, Vytrus Biotech S.A. would have to grow free cash flow by +54.4 % per year for five years (discount rate 14.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +37.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of VYT use?
Our models discount Vytrus Biotech S.A. at 14.1 %: a base by market capitalisation (micro), country premium for Spain. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vytrus Biotech S.A. that is +54.4 % per year a year over ten years, using the same discount rate (14.1 %) and the same formula as our fair value.
How much growth has Vytrus Biotech S.A. (VYT) delivered so far?
Over the past 5 years revenue at Vytrus Biotech S.A. grew +37.5 % a year. The price currently implies +54.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vytrus Biotech S.A. (VYT) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Vytrus Biotech S.A. (+54.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vytrus Biotech S.A. (VYT)?
The free-cash-flow yield on the price is 1.00 %: that much free cash flow Vytrus Biotech S.A. produces per unit of market value. When it exceeds the discount rate of our models (14.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vytrus Biotech S.A. (VYT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vytrus Biotech S.A. it is €13.94 per share (as of Sep 23, 2026), against a price of €16.20. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Vytrus Biotech S.A. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, VYT trades above its calculated fair value: price €16.20, fair value €13.94, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VYT?
No. The price is what the market pays today (€16.20); the fair value is what the company's own numbers justify (€13.94). For Vytrus Biotech S.A. the two are €2.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vytrus Biotech S.A. worth?
The market values Vytrus Biotech S.A. at about €132M (market capitalisation, as of Sep 23, 2026). Per share that is €16.20; our models calculate a fair value of €13.94 per share.
What do the bullish and bearish scenarios say about VYT?
Our models span a range for Vytrus Biotech S.A.: cautious scenario €5.72, base €13.94, optimistic €17.52 per share (as of Sep 23, 2026, price €16.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VYT?
Vytrus Biotech S.A. trades at a price-to-earnings ratio of 42.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €13.94 is built from several models across several years. Other multiples: P/B 14.5, P/S 15.4, EV/EBITDA 43.6.
How solid is the balance sheet of Vytrus Biotech S.A. (VYT)?
Balance-sheet figures for Vytrus Biotech S.A. (as of Sep 23, 2026): return on equity 32.9%, debt of 0.15 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is VYT from its 52-week high?
Vytrus Biotech S.A. trades at €16.20, about 18% below its 52-week high of €19.80 and 197% above the low of €5.45 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €13.94 is for.
Which stocks are comparable to Vytrus Biotech S.A.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vytrus Biotech S.A. stock attractive at the current price?
The data as of Sep 23, 2026: price €16.20, calculated fair value €13.94 (−14%), Quality Score 65/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VYT calculated?
We run Vytrus Biotech S.A. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €13.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Vytrus Biotech S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vytrus Biotech S.A. (VYT)?
The closing price on Sep 24, 2026 was €16.20. Our model-based fair value is €13.94, about −14% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vytrus Biotech S.A. right now?
The model range is unusually wide (€5.72 to €17.52). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Vytrus Biotech S.A.

How large is the market capitalisation of Vytrus Biotech S.A. (VYT)?
The market capitalisation of Vytrus Biotech S.A. is €132M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vytrus Biotech S.A. (VYT)?
The price-to-sales ratio of Vytrus Biotech S.A. is 14.7 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vytrus Biotech S.A. (VYT)?
Earnings per share at Vytrus Biotech S.A. are €0.3800 (price ÷ EPS = P/E 42.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vytrus Biotech S.A. (VYT)?
The net margin of Vytrus Biotech S.A. is 34.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vytrus Biotech S.A. (VYT)?
The return on equity (ROE) of Vytrus Biotech S.A. is 32.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vytrus Biotech S.A. (VYT)?
On an EBIT basis the return on assets of Vytrus Biotech S.A. is 9.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vytrus Biotech S.A. (VYT)?
The operating margin of Vytrus Biotech S.A. is 32.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vytrus Biotech S.A. (VYT)?
Revenue at Vytrus Biotech S.A. is growing +52.6% versus a year earlier (3y avg +31.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vytrus Biotech S.A. (VYT)?
Earnings per share at Vytrus Biotech S.A. are growing +185% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vytrus Biotech S.A. (VYT) carry?
The net debt of Vytrus Biotech S.A. is €1.7M (fiscal year 2023, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vytrus Biotech S.A. in the live analysis

One click puts Vytrus Biotech S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.